StemCyte and Fulgent Genetics Partner to Provide Comprehensive Genetic Analysis for Families
Published: Oct 09, 2018
BALDWIN PARK, Calif., Oct. 9, 2018 /PRNewswire/ -- StemCyte, a global regenerative therapeutics company, and Fulgent Genetics (NASDAQ:FLGT), a leading genetic testing company, are proud to announce a new partnership to offer comprehensive genetic testing to support the health of growing families. Two genetic tests, "Beacon Expanded Carrier Screening" and "Newborn Genetic Analysis (NGA)," will now be offered through StemCyte and powered by Fulgent Genetics.
Beacon Expanded Carrier Screening can help identify potential reproductive risks for current or future pregnancies. A carrier does not have signs or symptoms of a genetic disorder, but does carry a risk of having a child affected with a disorder. Awareness of an individual's carrier status can help them make more informed decisions for themselves and their families.
While Beacon Expanded Carrier Screening is intended to identify genetic risks present in parents, Newborn Genetic Analysis (NGA) is a unique test performed for newborns. NGA identifies DNA changes that could cause severe or life-altering symptoms in an infant. This analysis includes 255 genes and assesses over 200 disorders, covering many conditions beyond state legislated standards for newborn screening. NGA tests for early-onset conditions where early detection, intervention, and management could prove essential for the infant's overall health and quality of life.
Of the partnership, CEO of StemCyte Dr. Jonas Wang says, "We welcome our pregnant parents to enjoy the unique benefit [of genetic screening] for their family planning and reproductive health for a lifetime."
Ming Hsieh, Chairman and CEO of Fulgent Genetics, says, "We are excited to leverage the technology from our Beacon Carrier Screening and NGA tests to partner with StemCyte on their comprehensive family screening offering. We look forward to helping families make more informed health decisions now and in the future."
StemCyte's rich history started with a mission of being dedicated to helping the world's physicians save more lives by providing high quality, safe, and effective stem cell transplantation and therapy to all patients in need. Located in the US, India, and Taiwan, StemCyte has supplied close to 2,200 cord blood units for a variety of life-threatening diseases to over 350 leading worldwide transplant centers. StemCyte is actively involved in the development of stem cell therapies. StemCyte has also been chosen by the US Department of Health and Human Services to help establish a Public National Cord Blood Inventory. Its headquarters is located in Baldwin Park, CA. To learn more, visit www.StemCyte.com.
About Fulgent Genetics
Fulgent Genetics is a technology company with a focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its test menu, which currently offers more genes for testing than its competitors in today's market, enables it to provide expansive options for test customization and clinically actionable results.
Company Codes: NASDAQ-NMS:FLGT